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338 The Journal of Thoracic and Cardbjectives: We sought to assess the effects of cardiopulmonary bypass and pro-
ound hypothermic circulatory arrest on plasma cefazolin levels administered for
ntimicrobial prophylaxis in cardiovascular surgery.
ethods: Four groups (10 patients per group) were prospectively studied: vascular
urgery without cardiopulmonary bypass (group A), cardiac surgery with a cardio-
ulmonary bypass time of less than 120 minutes (group B), cardiac surgery with a
ardiopulmonary bypass time of greater than 120 minutes (group C), and cardiac
urgery with cardiopulmonary bypass and profound hypothermic circulatory arrest
group D). Subjects received cefazolin at induction and a second dose before wound
losure. Arterial blood samples were obtained preceding cefazolin administra-
ion, at skin incision, hourly during the operation, and before redosing. Cefa-
olin plasma concentrations were determined by using a radial diffusion assay,
ith Staphylococcus aureus as the indicator microorganism. Cefazolin plasma
oncentrations were considered noninhibitory at 8 g/mL or less, intermediate at 16
g/mL, and inhibitory at 32 g/mL or greater.
esults: In group A cefazolin plasma concentrations remained greater than 16
g/mL during the complete surgical procedure. In group B cefazolin plasma
oncentrations diminished to 16 g/mL or less in 30% of the patients but remained
reater than 8 g/mL. In group C cefazolin plasma concentrations decreased to less
han 16 g/mL in 60% of patients and were less than 8 g/mL in 50% of patients.
n group D cefazolin plasma concentrations reached 16 g/mL in 66% of the
atients but decreased to 8 g/mL in only 1 patient.
onclusions: For patients undergoing cardiac surgery with a cardiopulmonary
ypass time of greater than 120 minutes, a single dose of cefazolin before skin
ncision with redosing at wound closure does not provide targeted antimicrobial
efazolin plasma levels during the entire surgical procedure. Patients undergoing
rofound hypothermic circulatory arrest are better protected, but the described
rotocol of prophylaxis is not optimal.
ostoperative infection in cardiac surgical patients, mainly caused by Staphyl-
coccus aureus and coagulase-negative staphylococci,1 is a cause of major
morbidity and mortality. According to the National Heart, Lung, and Blood
nstitute–National Institute of Allergy and Infectious Diseases Working Group,
ardiovascular infections caused by S aureus are a serious national medical problem,
ith increases in the rate of S aureus bacteremia ranging from 122% to 283% in
ndividual hospitals.2
Antimicrobial prophylaxis with cephalosporin is used routinely to reduce surgi-al infections after cardiovascular surgery. The use of cardiopulmonary bypass
iovascular Surgery ● June 2006
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PCPB), particularly in conjunction with profound hypother-
ic circulatory arrest (PHCA), causes substantial profound
erturbations in hemodynamics, end-organ blood flow, and
emperature. Because of these changes and their influence
n antibiotic pharmacokinetics, the following investigation
as undertaken to determine the effect of CPB and PHCA
n cefazolin plasma levels administered for antimicrobial
rophylaxis in patients undergoing cardiovascular surgery.
ethods
fter obtaining the approval of the Stanford Institutional Review
oard and individual written informed consent, a total of 40
atients were prospectively enrolled in the study and assigned to
he following groups: group A, 10 patients undergoing vascular
urgery (no CPB); group B, 10 patients undergoing cardiac surgery
ith a CPB time of less than 120 minutes; group C, 10 patients
ndergoing cardiac surgery with a CPB time of greater than 120
inutes; and group D, 10 patients undergoing cardiac surgery with
he use of CPB and PHCA (Table 1).
In groups B and C the target systemic (bladder) temperature
as 28°C to 30°C. In group D the patients were systemically
ooled during CPB to a tympanic membrane temperature of 20°C.
uring the PHCA period, selective antegrade cerebral perfusion
as supplied through a right axillary artery cannula, with a flow of
0 mL/kg cold blood. Hydrocortisone (1 mg/kg), mannitol (0.5
/kg), and thiopentone (15 mg/kg) were administered before the
nitiation of PHCA.
Other than the above mentioned differences, all participants
eceived the same preoperative, operative, and postoperative care
s nonparticipants.
Cefazolin, 1 g administered intravenously (first dose), was
dministered immediately after the induction of anesthesia, and a
econd dose was administered just before wound closure (second
ose). In group A arterial blood samples drawn from a radial artery
atheter were obtained before the first cefazolin dose, at skin
ncision, at every hour of surgical intervention, and just before the
econd dose of cefazolin. In groups B, C, and D additional samples
ere obtained before the initiation of CPB, every hour during
PB, and after weaning from CPB.
Blood samples were centrifuged, and serum was frozen to
80°C before analysis. The antibiotic plasma level (in micro-
rams per milliliter) of cefazolin (Cp) was then determined in vitro
y using a biologic radial diffusion assay, with S aureus as the
ndicator organism.3 Three levels of inhibition were identified: a
p of 32 g/mL or greater was targeted as inhibitory to S aureus,
Cp of 16 g/mL was intermediate, and a Cp of 8 g/mL or less
as considered to be not inhibitory.
Data are reported as means (standard deviation) and incidence
f observations, unless indicated otherwise. Differences between
Abbreviations and Acronyms
Cp  plasma cefazolin level
CPB cardiopulmonary bypassroups were analyzed by using analysis of variance. The Tukey a
The Journal of Thoracicethod was used for multiple comparisons. For each surgical
roup, Kaplan-Meier actuarial estimates were calculated to quan-
ify the time from cefazolin administration to a decrease in con-
entration to less than 32, 16, and 8 g/mL; differences between
urves were determined by using the log-rank test. All analyses
ere performed with S-PLUS version 6.2 software (Insightful
orp, Seattle, Wash).
esults
he demographic data of the patients are presented in Table 2.
ne patient in group D was removed from analysis because
f surgical complications, including severe hemorrhage.
here was no difference in age, body mass index, or pre-
perative serum creatinine value between the groups. In
roup C the temperature reached a significantly lower level
P  .01), and the CPB time was significantly longer (P 
01) than in group B. There was no difference in mean
urgical time between groups A and B or between groups C
nd D. CPB and surgical times were significantly longer in
roups C and D (P  .01) compared with that in group B.
The plasma concentration time course of individual pa-
ients in each group is depicted in Figure 1. In group A Cp
emained greater than 16 g/mL during the complete sur-
ical procedure. Cp diminished to 16 g/mL or less in 30%
f the patients in group B, in 60% of the patients in group
, and in 66% of the patients in group D. The Kaplan-Meier
urvival curves (Figure 2) show that in group C in 50% of
he patients, Cp reached plasma levels of 8 g/mL or less,
ABLE 1. Types of operations by groups
roups Operations (n)
Abdominal aortic aneurysm repair (5)
Thoracic aortic aneurysm (2)
Aortofemoral bypass (2)
Femoral-popliteal bypass (1)
Coronary artery bypass grafting (5)
Aortic valve replacement (2)
Mitral valve replacement (1)
Tricuspid pulmonary valve replacement (1)
Ascending aortic aneurysm (1)
Aortic valve and ascending aortic aneurysm
replacement (4)
Aortic, mitral, and tricuspid valve
replacement (1)
Aortic and mitral valve replacement (2)
Aortic valve replacement and coronary artery
bypass grafting (2)
Thoracic aortic aneurysm (1)
Ascending aorta and arch replacement (5)
Aortic valve, ascending aorta, and arch
replacement (3)
Thoracic aorta and arch replacement (2)nd in group D this was true in 1 patient.
and Cardiovascular Surgery ● Volume 131, Number 6 1339
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CSPFigure 2 shows the survival probabilities for concentra-
ions greater than 32, 16, and 8 g/mL. Differences between
roups A, B, C, and D were not significant; however, there
as a trend favoring a higher probability of concentrations
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Figure 1. The cefazolin plasma concentration (Cp) time
of 8 g/mL or less was considered to be not inhibitory
a Cp of 32 g/mL or greater was considered to be inh
ABLE 2. Demographic data
roup (n) A (10)
ge (y) 66.9 10.6*
MI (kg/m2) 26.8 4.7
reatinine 1.1 0.2
ale/female sex (n) 7/3
PB time (min) NA 1
urgical time (min) 245.5 70.6 2
owest temp (°C) 35.2 0.4
MI, Body mass index; CPB, cardiopulmonary bypass; temp, bladder tem340 The Journal of Thoracic and Cardiovascular Surgery ● Junreater than 32 g/mL in group D (P .08). In group A, B,
, and D the median time for concentrations greater than 32
g/mL was 265, 210, 229, and 349 minutes, respectively.
ll patients in groups A and B had concentrations greater
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rse of individual patients in each surgical group. A Cp
p of 16 g/mL was considered to be intermediate, and
ry to S aureus.
(10) C (10) D (9)
 15.4 50.1  16.8 62.0 17.3
 4.6 25.9  4.2 24.8 3.5
 0.1 1.0  0.4 1.0 0.3
/3 5/5 6/4
 24.2 215.2  75.7 216.7 55.6
 70.0 447.5  119.5 500.0 104.0
 1.7 28.1  2.3 21.2 0.5
re. *Standard deviation.cou
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Phan the noninhibitory level (8 g/mL); however, in group
the probability of concentrations of greater than 8 g/mL
as 86% compared with group C, in which the probability
f concentrations greater than 8 g/mL was only 51%
efore administration of the second dose of cefazolin.
iscussion
hese observations demonstrate that Cp is not changed by
PB times of less than 120 minute with mild-to-moderate
ypothermia, but in procedures requiring prolonged CPB
ime (120 minutes) and PHCA, the dosing schedule used
as not adequate to maintain targeted plasma concentra-
ions of cefazolin.
The incidence of postoperative infection after cardiac
urgery is reported to be between 7% and 18%, including
eep sternal wound infections between 1% and 3%.4 Infec-
ion is associated with increased morbidity, mortality (up to
0%),5 hospital stay,6 and costs.7 Toumpoulis and col-
eagues8 recently showed a 3-fold increase in 10-year mor-
ality after initial recovery from deep sternal wound infec-
ion after coronary artery bypass surgery.
Cephalosporins, including cefazolin, are the most suit-
ble prophylactic antibiotics because they are bacteri-
idal, nontoxic, and active against the most common
icroorganisms, such as S aureus, Staphylococcus epi-
ermidis, and Enterobacter species.1,9 Cefazolin is 100%
liminated by the kidneys and 80% to 85% bound to
rotein.10 Pharmacokinetic parameters of cefazolin have
een determined during surgical intervention by using a
odel-independent method, showing an elimination half- e
The Journal of Thoracicife of 231 minutes, a total body clearance of 1.05 mL ·
g1 · min1, and a steady-state volume of distribution
f 243 mL/kg.11
The prophylactic dosing schedule of cefazolin remains
ontroversial. The recommended dose in vascular and un-
omplicated cardiac surgery is 1 to 2 g administered intra-
enously every 8 hours for 24 to 48 hours,12 although single
reoperative dose prophylaxis is often used. Bucknell and
ssociates13 showed that a single dose of cefazolin, 1 g
dministered intravenously, before incision was as effective
s redosing during 48 hours in cardiac surgery cases with a
hort CPB time (120 minutes). In more prolonged proce-
ures (surgical time 240 minutes) intraoperative redosing
f cefazolin appeared to be effective in reducing surgical
nfection, in which the second dose of cefazolin is usually
dministered at fixed intervals,14 instead of related to specific
tages of the operative procedure, as in our study. Others
dminister a second dose of cefazolin immediately after the
nset of CPB,4 arguing that the physiologic changes associated
ith CPB might rapidly decrease the effective plasma level of
he drug. Naziri and coworkers15 proposed administering an-
ibiotic prophylaxis continuously during surgical intervention
o achieve constant plasma levels.
In our study the results show that the first dose of
efazolin was administered at the appropriate time before
kin incision, as recommended,16 and the Cp at incision time
as inhibitory (32 g/mL) in all patients. Our choice of
edosing just before wound closure has not been reported
Figure 2. Kaplan-Meier survival curves for
cefazolin concentrations greater than 32,
16, and 8 g/mL in groups A, B, C, and D.lsewhere. Our argument is based on the notion that during
and Cardiovascular Surgery ● Volume 131, Number 6 1341
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CSPncision and skin closure, contamination of the wound is
ikely to occur. The reason for the timing of the last test
ample was to verify whether our choice of redosing timing
rovided targeted plasma levels of cefazolin against micro-
rganisms like S aureus.
Group A was the control group because CPB is not
eeded during vascular surgical operations and cephalospo-
in pharmacokinetics are predictable. This study showed
hat within the time period assessed for group A, cefazolin
lasma levels stayed in the therapeutic range for the most
ommon gram-positive organism causing postoperative in-
ection, suggesting that patients are well protected against
 aureus in accordance with earlier studies.17 In the 3
emaining groups, CPB was used. The effects of CPB on the
harmacokinetics of cefazolin might include changes in
olume of distribution and protein binding, mainly caused
y a decreased temperature, hemodilution, and changes in
rgan perfusion.
Group B patients were comparable with subjects in ear-
ier investigations, including a relatively short CPB time
nd mild hypothermia.13 It is appropriate to compare group
with group A because age, body mass index, serum
reatinine value, and surgical time were not statistically
ifferent. The results show that CPB with mild hypothermia
oes not change the plasma concentrations of cefazolin and
hat the dosing and timing schedule used kept the plasma
efazolin levels in the therapeutic range against S aureus.
he renal clearance of cefazolin, although not measured, is
pparently preserved, which might be due to the effect of
emodilution, compensating for the lower temperature.
CPB time has not been examined often in earlier studies
ecause the length of the surgical procedure is considered to
e a more important risk factor for postoperative infec-
ion.14 Our approach of using a CPB time of greater than
20 minutes as risk factor is based on the premise that
rolonged CPB might cause substantial organ dysfunction.
his could lead to renal dysfunction and substantial fluid
hifts. In group C, with statistically longer CPB and oper-
tive times (both P  .01) and a lower mean minimal
emperature (P  .01) than in group B, the results showed
hat cefazolin plasma levels decreased to intermediate ther-
peutic levels in 60% of the patients and to ineffective
evels in 50% of patients with respect to S aureus prophy-
axis. This indicates that our choice of redosing time in this
roup of patients was suboptimal. A CPB time of 120
inutes is apparently a cutoff point, and the expected decrease
n cefazolin excretion rate does not occur but instead follows
he normal time scale, despite the lower temperature.
Patients undergoing PHCA (group D) have not previ-
usly been studied with respect to antibiotic prophylaxis.
lthough the mean CPB and operation times in groups C
nd D were not significantly different, only 1 patient in
roup D had a completely subtherapeutic (8 g/mL)
342 The Journal of Thoracic and Cardiovascular Surgery ● Junlasma level. Thus PHCA changes the pharmacokinetics of
efazolin considerably more than merely long CPB time,
hifting the curve of the plasma level to the right. This
ndicates that excretion of cefazolin is delayed and that
HCA prolongs the duration of targeted cefazolin plasma
evels.
Several alternative prophylactic treatments for groups C
nd D can be proposed, including a higher initial dose
according to body weight; ie, 30 mg/kg cefazolin), a sec-
nd dose at the onset of CPB, or redosing every 240
inutes. It can be predicted that all these dosing schedules
ill improve the efficacy of prophylaxis in these patients,
ut randomized comparative studies should elucidate which
rophylaxis regimen is optimal, particularly for patients
equiring prolonged CPB time.
This study has several limitations. We did not measure
issue levels of cefazolin, as is recommended by others,18
lthough tissue levels are reported to be directly related to
efazolin plasma levels.19 It might even be unclear whether
he laboratory technique measuring effective plasma levels
s accurate to predict risk of infection because Maki and
olleagues20 observed 12% surgical wound infections after
ardiac surgery in patients similar to our patients in group B
n the presence of effective cefazolin plasma levels through-
ut surgical intervention. In our study surgical site infection
as observed in 3 patients (1 in group B and 2 in group D),
ll with superficial infections and no cases of mediastinitis.
utcome studies with a larger number of patients would be
eeded to assess whether lower plasma levels of cefazolin in
roups C and D actually correlated with a higher incidence
f postoperative surgical site infections. Our choice for
nalyzing CPB time instead of surgical time as a discrimi-
ating factor can be criticized. It was mainly related to our
outine to redose cefazolin at the start of wound closure and
ot to a fixed time interval.
We conclude that in patients undergoing long, compli-
ated cardiac surgical procedures, our routine cefazolin
rophylaxis schedule did not provide targeted plasma levels
or all patients and that alternative techniques should be
nvestigated, particularly in cardiac cases with moderate
ypothermia and a prolonged CPB time.
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